

# PRODUCT INFORMATION




## NX-1607

Item No. 45222

**CAS Registry No.:** 2573775-59-2  
**Formal Name:** 2,3-dihydro-2-[3-[*cis*-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-6-[[*(3S)*-3-methyl-1-piperidinyl]methyl]-4-(trifluoromethyl)-1H-isoindol-1-one

**Synonym:** Cbl-b-IN-3  
**MF:** C<sub>30</sub>H<sub>34</sub>F<sub>3</sub>N<sub>5</sub>O  
**FW:** 537.6  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

NX-1607 is supplied as a solid. A stock solution may be made by dissolving the NX-1607 in the solvent of choice, which should be purged with an inert gas. NX-1607 is sparingly soluble (1-10 mg/ml) in ethanol and DMSO.

### Description

NX-1607 is an inhibitor of casitas B-lineage lymphoma proto-oncogene b (Cbl-b; IC<sub>50</sub> = 3.4 nM), a RING-type E3 ubiquitin ligase that negatively regulates T cell function.<sup>1</sup> It increases IL-2 secretion in primary human T cells (EC<sub>50</sub> = 180.6 nM). Application of NX-1607 to anti-CD19 chimeric antigen receptor T (CAR-T) cells generated from patients with diffuse large B cell lymphoma (DLBCL) increases the number of CAR-T cells formed during expansion.<sup>2</sup> NX-1607 also increases the production of IFN-γ, TNF-α, IL-2, and granzyme B in the same CAR-T cells and enhances the cytotoxicity of the CAR-T cells in Raji, Daudi, and SU-DHL-4 cells. It enhances the antitumoral efficacy of anti-CD19 CAR-T cells in a Raji B cell lymphoma mouse xenograft model. NX-1607 (5 mg/kg) also reduces alanine transaminase (ALT) and aspartate aminotransferase (AST), markers of liver injury, and hepatic fibrosis in methionine- and choline-deficient (MCD) diet, carbon tetrachloride (CCl<sub>4</sub>), and bile duct ligation (BDL) models of liver fibrosis.<sup>3</sup>

### References

1. Meng, F., Cao, Z., Liu, J., *et al.* Discovery and biological evaluation of novel, potent, and orally available CBLB inhibitors. *J. Med. Chem.* **68(22)**, 24502-24518 (2025).
2. Wang, H., Li, F., Feng, Y., *et al.* Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. *Int. Immunopharmacol.* **147:113971**, (2025).
3. Lu, K., Xu, Y., He, L., *et al.* Revisiting the role of CBL in liver fibrosis: Unveiling the antifibrotic potential of CBLB inhibitor NX-1607. *J. Hepatol.* **83(3)**, e175-e177 (2025).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/092026

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM